Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis (original) (raw)
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
Virgilio Eugenio Arenas Fuentes
Addiction (Abingdon, England), 2017
View PDFchevron_right
Integration of care for HIV and opioid use disorder
Nicolas Muñoz
AIDS, 2018
View PDFchevron_right
Perspectives on the HIV continuum of care among adult opioid users in New York City: a qualitative study
Crystal Fuller Lewis
Harm Reduction Journal, 2019
View PDFchevron_right
“Chasing the pain relief, not the high”: Experiences managing pain after opioid reductions among patients with HIV and a history of substance use
Kelly Knight
PLOS ONE, 2020
View PDFchevron_right
Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial
Kim Hoffman
BMC Health Services Research, 2019
View PDFchevron_right
Participant Characteristics and HIV Risk Behaviors Among Individuals Entering Integrated Buprenorphine/Naloxone and HIV Care
Barbara Estrada
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
View PDFchevron_right
HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Adan Cajina
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
View PDFchevron_right
The medical management of opioid dependence in HIV primary care settings
Paula Lum
Current HIV/AIDS Reports, 2006
View PDFchevron_right
Engaging People Who Inject Drugs Living With HIV in Antiretroviral Treatment and Medication for Opioid Use Disorder: Extended Follow-up of HIV Prevention Trials Network (HPTN) 074
Zubairi Djoerban
Open Forum Infectious Diseases, 2021
View PDFchevron_right
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Sandra Springer
Drug and alcohol dependence, 2015
View PDFchevron_right
Chronic Opioid Therapy in HIV-infected Patients: Patients' Perspectives on Risks, Monitoring and Guidelines
Jane Liebschutz
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018
View PDFchevron_right
Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders
Suzette Glasner-edwards
Journal of Substance Abuse Treatment, 2017
View PDFchevron_right
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Frederick Altice
Contemporary clinical trials, 2014
View PDFchevron_right
Expanding the impact of opioid agonist therapy for opioid use disorder -Are there lessons from the HIV/AIDS response
Jan Klimas
Addiction, 2020
View PDFchevron_right
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial
Vladimir Palatkin
The Lancet HIV
View PDFchevron_right
Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network
Bruce Burchett
Substance Abuse and Rehabilitation, 2010
View PDFchevron_right
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Sandra Springer
Current HIV/AIDS Reports, 2019
View PDFchevron_right
Patient and provider perspectives on implementation barriers and facilitators of an integrated opioid treatment and HIV care intervention
Dorothy Mushi
Addiction Science & Clinical Practice, 2019
View PDFchevron_right
Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach
Bruno Spire
Harm Reduction Journal, 2011
View PDFchevron_right
Facing Opioids in the Shadow of the HIV Epidemic
Caroline Parker
New England Journal of Medicine, 2019
View PDFchevron_right
Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder
Sandra Springer
Contemporary Clinical Trials Communications, 2021
View PDFchevron_right
Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study
Ajay Manhapra
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
View PDFchevron_right
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Nicolas Muñoz
Journal of Substance Abuse Treatment, 2018
View PDFchevron_right
Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment
Ariadna Forray
Substance Abuse, 2021
View PDFchevron_right
Extended-Release Naltrexone Improves Viral Suppression among Incarcerated Persons Living with HIV with Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial
Sandra Springer
Journal of acquired immune deficiency syndromes (1999), 2018
View PDFchevron_right
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Amy Justice
AIDS and behavior, 2018
View PDFchevron_right
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Lynn Sullivan
Clinical Infectious Diseases, 2006
View PDFchevron_right
Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
Lars Tanum
Addiction Science & Clinical Practice
View PDFchevron_right